Company research / LCTX
Lineage Cell Therapeutics, Inc. (LCTX)
- Sector Manufacturing
- Incorporated CA
- Fiscal year ends Dec 31
For the year ended 2025-12-31, Lineage Cell Therapeutics, Inc. reported revenue of $14.56M. Revenue grew 53.2% from the prior annual period.
Key ratios (year ended 2025-12-31)
-251.6%
Operating margin
-436.5%
Net margin
-146.6%
Return on year-end equity
53.2%
Revenue growth (YoY)
Beyond the statements
Follow the company.
Explore new filings, reported insider transactions and company relationships.